Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
-
SoSe 2022
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AMLIn: HemaSphere: Open Access Journal of the European Hematology Association, Jg. 9, 2025, Nr. 5, e70132DOI (Open Access)
-
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patientsIn: Leukemia, 2025, in pressDOI (Open Access)
-
Gastrointestinal toxicity of gemtuzumab ozogamicin : real-life data from the AMLCG, SAL, and CELL study groupsIn: Blood Advances, Jg. 9, 2025, Nr. 13, S. 3336 – 3339DOI (Open Access)
-
Gemtuzumab ozogamicin in first-line treatment of CBF-AML : Insights from a retrospective multi-center analysisIn: Leukemia, Jg. 39, 2025, Nr. 9, S. 2174 – 2180DOI (Open Access)
-
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibitionIn: Cancer Cell, 2025, in pressDOI (Open Access)
-
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia : long-term follow-up with focus on younger patientsIn: Blood Cancer Journal, Jg. 15, 2025, Nr. 1, 60DOI (Open Access)
-
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML : The Randomized DaunoDouble Trial by the Study Alliance LeukemiaIn: Journal of Clinical Oncology (JCO), Jg. 43, 2025, Nr. 1, S. 65 – 74
-
VINCENT : A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLIn: Annals of Hematology, Jg. 104, 2025, Nr. 7, S. 3647 – 3654DOI (Open Access)
-
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaIn: Blood Advances, Jg. 9, 2025, Nr. 6, S. 1392 – 1404DOI (Open Access)
-
Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML : Results from the SAL-MODULE phase I studyIn: British Journal of Haematology, Jg. 204, 2024, Nr. 6, S. 2254 – 2258DOI (Open Access)
-
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALLIn: Journal of Clinical Oncology (JCO), Jg. 42, 2024, Nr. 3, S. 273 – 282
-
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligenceIn: npj Digital Medicine, Jg. 7, 2024, Nr. 1, 76DOI (Open Access)
-
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensIn: Haematologica / The Hematology Journal, Jg. 109, 2024, Nr. 8, S. 2469 – 2477DOI (Open Access)
-
Alterations of cohesin complex genes in acute myeloid leukemia : Differential co-mutations, clinical presentation and impact on outcomeIn: Blood Cancer Journal, Jg. 13, 2023, Nr. 1, 18DOI (Open Access)
-
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4In: Haematologica / The Hematology Journal, Jg. 108, 2023, Nr. 1, S. 34 – 41DOI (Open Access)
-
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemiaIn: Haematologica / The Hematology Journal, Jg. 108, 2023, Nr. 7, S. 1758 – 1767DOI (Open Access)
-
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy : A real-world registry experienceIn: British Journal of Cancer (BJC), Jg. 129, 2023, Nr. 7, S. 1126 – 1133DOI (Open Access)
-
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit : Real-world data from the German SAL-AML registryIn: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 8, S. 4611 – 4621DOI (Open Access)
-
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaIn: Leukemia, Jg. 37, 2023, Nr. 12, S. 2395 – 2403DOI (Open Access)
-
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningIn: Haematologica / The Hematology Journal, Jg. 108, 2023, Nr. 3, S. 690 – 704DOI (Open Access)
-
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia : Implications for the European leukemia net risk classificationIn: Leukemia, Jg. 37, 2023, Nr. 11, S. 2282 – 2285DOI (Open Access)
-
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profilesIn: Communications Medicine, Jg. 3, 2023, Nr. 1, 68DOI (Open Access)
-
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationIn: Journal of Hematology and Oncology, Jg. 15, 2022, Nr. 1, 126DOI (Open Access)
-
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsIn: Journal of Hematology and Oncology, Jg. 15, 2022, Nr. 1, 60DOI (Open Access)
-
Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapyIn: European Journal of Medical Research, Jg. 26, 2021, Nr. 1, 63DOI, Online Volltext (Open Access)
-
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition : A Descriptive Observational Retrospective Multicenter AnalysisIn: Frontiers in Oncology, Jg. 11, 2021, 765608DOI, Online Volltext (Open Access)
-
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaIn: Blood Advances, Jg. 5, 2021, Nr. 17, S. 3279 – 3289DOI (Open Access)
-
Rationale and design of the 2 by 2 factorial design GnG-trial : A randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLIn: Trials, Jg. 22, 2021, Nr. 1, 765DOI (Open Access)
-
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia : Long-term follow-up of the randomized controlled SORAML trialIn: Leukemia, Jg. 35, 2021, Nr. 9, S. 2517 – 2525DOI (Open Access)
-
Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosisIn: Scientific Reports, Jg. 11, 2021, Nr. 1, 22062DOI, Online Volltext (Open Access)
-
Acute myeloid leukemia–induced remodeling of the human bone marrow niche predicts clinical outcomeIn: Blood Advances, Jg. 4, 2020, Nr. 20, S. 5257 – 5268DOI (Open Access)
-
Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25–36] (European Journal of Cancer (2020) 124 (25–36), (S0959804919307555), (10.1016/j.ejca.2019.09.027))In: European Journal of Cancer (EJC), Jg. 136, 2020, S. 207 – 208
-
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma : Post-hoc analysis from the PETAL trialIn: European Journal of Cancer (EJC), Jg. 124, 2020, S. 25 – 36
-
Etoposide combined with FLAG salvage therapy is effective in multiple relapsed / refractory acute myeloid leukemiaIn: Acta Haematologica, Jg. 143, 2020, Nr. 5, S. 438 – 445DOI (Open Access)
-
Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitroIn: Blood Advances, Jg. 4, 2020, Nr. 13, S. 3000 – 3010DOI (Open Access)
-
Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determinationIn: Data in Brief, Jg. 28, 2020, 104976DOI (Open Access)
-
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantationIn: Nature Medicine, Jg. 25, 2019, Nr. 4, S. 603 – 611DOI (Open Access)
-
Nestin⁺NG2⁺ Cells Form a Reserve Stem Cell Population in the Mouse ProstateIn: Stem Cell Reports, Jg. 12, 2019, Nr. 6, S. 1201 – 1211DOI (Open Access)
-
Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemiaIn: International Journal of Hematology, Jg. 102, 2015, Nr. 3, S. 278 – 288
-
Acral ischemia as a presenting manifestation of essential thrombocythemiaIn: International Journal of Hematology, Jg. 94, 2011, Nr. 3, S. 219 – 220
-
The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia PatientsIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2025, Nr. Suppl. 1, S. 2934DOI (Open Access)
-
Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 2211DOI (Open Access) -
IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 631DOI (Open Access) -
Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies : a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 2179DOI (Open Access) -
Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia : Data from the GMALL Study GroupIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 1436 – 1437DOI (Open Access)
-
Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) : A Multicenter Real-World Analysis
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 3818DOI (Open Access) -
Trial in Progress : A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML- the SAL/AMLCG Vincent Trial
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 1527.1 – 1527.1DOI (Open Access) -
Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1-Mutated Acute Myeloid Leukemia Patients : Results from a Large Cohort of Intensively Treated Patients
65th Annual Meeting of the American-Society-of-Hematology (ASH); DEC 09-12, 2023; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 142, 2023, Nr. Suppl. 1, S. 721 – 721DOI (Open Access) -
Single vs double induction with "7+3" containing 60 vs 90 mg daunorubicin for newly diagnosed acute myeloid leukemia : results from the randomized controlled SAL-DaunoDouble trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 27DOI (Open Access) -
Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML : Updated Results of the Phase-I/II SAL Relax Trial
65th ASH Annual Meeting, December 9-12, 2023, San Diego, CA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 142, 2023, Nr. Supplement 1, S. 160 – 162DOI (Open Access) -
Venetoclax plus high-dose cytarabine and mitoxantrone as feasible and effective novel treatment for relapsed AML : results of the phase-I RELAX trial (SAL-AMLCG)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 26 – 27DOI (Open Access) -
Impact of IDH1 and IDH2 mutational subgroups in acute myeloid leukemia patients after allogeneic hematopoietic cell transplantationIn: Bone Marrow Transplantation. London: Springer Nature, Jg. 57, 2022, Nr. Suppl. 1, S. 17
-
Inotuzumab Ozogamicin Induction followed by Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 510 – 512DOI (Open Access) -
Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients : Excellent Outcome of Standard Risk Thymic T-ALL
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 115 – 117DOI (Open Access) -
Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML : Results from the Randomized Controlled SAL Dauno-Double Trial
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 523 – 525DOI, Online Volltext (Open Access) -
Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML : Results of the Phase-I SAL Relax Trial
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 3327 – 3328DOI (Open Access) -
Venetoclax and Hypomethylating Agents Followed by Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 12943 – 12944DOI (Open Access) -
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta, GA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 1307 – 1310DOI (Open Access) -
Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 2300 – 2302DOI (Open Access) -
Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy : A Real-World Registry Experience
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 3370 – 3371DOI (Open Access) -
Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 1242 – 1243DOI (Open Access) -
Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 108 – 110DOI (Open Access) -
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 33 – 35DOI (Open Access) -
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaIn: Blood Cancer Journal. London: Springer Nature, Jg. 11, 2021, Nr. 10, 164DOI (Open Access)
-
Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 4418 – 4420DOI (Open Access) -
Dynamic model for risk assessment in diffuse large B-cell lymphoma based on positron emission tomography scanning
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 42, 2019, Nr. Supplement 4: Abstracts, S. 67DOI (Open Access) -
Acute Myeloid Leukemia Induced Remodelling of the Human Bone Marrow Niche Predicts Clinical Outcome
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 132, 2018, Nr. Supplement 1, S. 3851 – 3851DOI (Open Access) -
Inhibition of CD38 Shows Anti-Leukemic Activity in Acute Myeloid Leukemia
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 132, 2018, Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 1456 – 1456DOI (Open Access) -
Cryptochrome 1 (CRY1) promoter methylation is associated with good prognosis in B-cell chronic lymphocytic leukemia (CLL)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 6, S. 240 – 241 -
Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence
65th ASH Annual Meeting, December 9-12, 2023, San Diego, CA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 142, 2023, Nr. Supplement 1, S. 2268 – 2270DOI (Open Access) -
Real-world experience with hypomethylating agents and venetoclax as induction or salvage therapy followed by allogeneic stem cell transplantation in patients with acute myeloid leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 193DOI (Open Access) -
Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment : A Propensity Score Matching Analysis
64th Annual Meeting and Exposition of the American Society of Hematology, December 10 - 13, 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 3317 – 3319DOI (Open Access)